Evidence map›Paper›PMID 36379404›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2023

Clinical characteristics of patients with coronavirus disease 2019-associated pulmonary aspergillosis on mechanical ventilation: A single-center retrospective study in Japan.

Yoshihiko Ogawa, Kenya Murata, Kohei Hasegawa, Koji Nishida, Iwao Gohma, Kei Kasahara

Open access · bronzeAbstract read
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Risk factors for identifying pulmonary aspergillosis in pediatric patients.Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yoshihiko OgawaDepartment of Infectious Diseases, Sakai City Medical Center, Sakai, Osaka, Japan. Electronic address: hikoichi.ogw@gmail.com.
Kenya MurataDepartment of Infectious Diseases, Sakai City Medical Center, Sakai, Osaka, Japan.
Kohei HasegawaDepartment of Infectious Diseases, Sakai City Medical Center, Sakai, Osaka, Japan.
Koji NishidaDepartment of Respiratory Medicine, Sakai City Medical Center, Sakai, Osaka, Japan.
Iwao GohmaDepartment of Respiratory Medicine, Sakai City Medical Center, Sakai, Osaka, Japan.
Kei KasaharaCenter for Infectious Diseases, Nara Medical University, Nara, Japan.
Sakai Municipal Hospital · JPNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAspergillus is one of the important pathogens that contribute to high mortality in patients with coronavirus disease 2019 (COVID-19) in intensive care units (ICUs). Although incidence rates of Aspergillus coinfection are high globally, a Japanese national survey reported a low incidence. This study aimed to describe the clinical characteristics of patients with COVID-19-associated pulmonary aspergillosis at our institute.

methodsWe identified patients with microbiologically confirmed COVID-19 on mechanical ventilation in the ICU. Of these patients, we identified patients in whom Aspergillus was cultured from the respiratory specimen.

resultsOf a total of 169 patients, seven had aspergillosis (4.1%), which included three patients, three patients, and one patient with possible, probable, and proven aspergillosis, respectively, according to the criteria of the European Confederation of Medical Mycology International Society. All patients received systemic steroid therapy. Two patients (one each with proven and probable aspergillosis) had tracheobronchitis diagnosed by bronchoscopy. All patients in whom Aspergillus was repeatedly isolated from samples died. The mortality rates for all cases and probable and proven cases were 57% (4/7) and 75% (3/4), respectively.

conclusionsThe incidence rate of aspergillosis in patients with COVID-19 in the ICU was higher in our institute than that reported by a Japanese national survey (4.1% vs. 0.5%). Repeated detection of Aspergillus might suggest a true Aspergillus infection, such as chronic aspergillosis, rather than colonization. In patients with severe COVID-19 patients, it is important to always keep CAPA in mind.

Indexed as

AspergillosisCOVID-19Invasive Pulmonary AspergillosisPulmonary AspergillosisAspergillusHumansJapanRespiration, ArtificialRetrospective StudiesAspergillosisBronchoscopyCOVID-19Mechanical ventilationTransbronchial aspirate

Identifiers

PMID36379404
PMCPMC9657892
OpenAlexW4309047222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.